Eli Lilly’s blockbuster drug Mounjaro (tirzepatide) has witnessed a remarkable surge in usage and sales in India, with June 2025 figures showing a twofold increase in volume to 87,968 units, compared to 42,281 units in May. The sales value rose by 18.2%, reaching ₹50 crore, up from ₹42.28 crore in the previous month.
The growth, tracked by PharmaRack, is attributed to faster onboarding of new patients and strong adherence among existing users. The 2.5 mg vial sales doubled from 19,346 to 39,042